Producer
TriLink BioTechnologies
San Diego-based mRNA capping reagent company (subsidiary of Maravai LifeSciences, MRVI); inventor of CleanCap co-transcriptional capping technology; near-monopoly during COVID-19 vaccine era with 350+ preclinical/clinical programs using CleanCap; revenue peaked at $883M (2022), fell to $259M (2024) after COVID demand collapse
2
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
2 inputs TriLink BioTechnologies supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something TriLink BioTechnologies makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
CleanCap® mRNA Capping Technology
52%Modified Nucleotides (m1Ψ, pseudoUTP, 5mC-UTP)
20%Custom mRNA CDMO Manufacturing
15%Research Reagents & Diagnostic Reference Standards
13%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Concentration2024
In February 2024, TriLink secured CleanCap patents in both China and Canada, extending its IP moat beyond the US and EU. For any Chinese domestic mRNA vaccine developer to legally use CleanCap, they must now license from a US company — or design around the patent. This geopolitical IP position makes CleanCap a potential US export control flashpoint if mRNA vaccine supply chains become politically contested.
MarketScreener / GlobeNewswire ↗Incident2023
TriLink/Maravai's revenue collapsed from $883 million (2022) to $259 million (2024) — a 71% drop — as COVID-19 mRNA vaccine manufacturing wound down. The company had scaled to serve a wartime demand surge that evaporated. This "cliff event" exposed the fragility of being a monopolist supplier to a single end-market application.
Maravai LifeSciences Investor Relations ↗Did you know2023
TriLink BioTechnologies — the near-monopoly supplier of CleanCap mRNA capping reagents for vaccine manufacturing — also produces the RNA quantification reference standards used to calibrate diagnostic PCR tests for HIV, hepatitis C, and COVID-19. TriLink's RNA standards are traceable reference materials: clinical labs compare patient samples against them to determine viral load and diagnose infection. A supply disruption at TriLink's San Diego facility would not only affect mRNA vaccine manufacturing programs but would also degrade the calibration accuracy of the PCR diagnostics that determine whether HIV-positive patients need to start or change antiretroviral therapy. The same company is simultaneously the critical ingredient supplier for therapeutic mRNA AND the calibration standard supplier for global infectious disease diagnostics — two entirely distinct roles in healthcare that happen to share the same RNA chemistry expertise and facility.
TriLink BioTechnologies ↗Capacity2023
TriLink BioTechnologies held near-monopoly power over the mRNA vaccine supply chain during 2021-2022. COVID-19 mRNA vaccines required CleanCap-type cap analogs — and TriLink was the only commercial-scale supplier. Maravai LifeSciences (TriLink's parent) reported revenue of $883M in 2022, almost entirely from TriLink's CleanCap supply to Pfizer-BioNTech and Moderna. By 2024 revenue had collapsed to ~$259M as COVID vaccine demand fell and pharma companies qualified alternative cap analog suppliers. The concentration risk was real: the entire COVID-19 mRNA vaccination program for billions of people ran through a single San Diego production facility. TriLink now faces competition from in-house capping enzyme programs (Pfizer, Moderna), European licensees, and Chinese cap analog producers — the monopoly premium is eroding.
Maravai LifeSciences Holdings, Inc. ↗Origin2023
TriLink BioTechnologies was founded in 1996 in San Diego by a group of nucleotide chemists focused on custom RNA synthesis and research reagents — a niche market with no obvious connection to global public health. In 2013, TriLink invented CleanCap®, a co-transcriptional capping technology that produces Cap 1 mRNA structures in a single enzymatic step rather than the two-step process used previously. This technical advance was obscure until 2020: when Moderna and Pfizer-BioNTech scaled mRNA COVID vaccine production, both required co-transcriptional capping at pharmaceutical scale. TriLink was the only commercial supplier of CleanCap-type reagents at the scale needed — transforming a San Diego research reagent company into a critical node in the global vaccine supply chain practically overnight. Maravai LifeSciences acquired TriLink before COVID; Maravai's stock (MRVI) rose 400%+ in 2021 as the scale of TriLink's dependency became apparent.
TriLink BioTechnologies (Maravai LifeSciences) ↗